Hemophilia A is a severe bleeding disorder caused by a deficiency in clotting factor Vlll (FVIII). A canine model that closely mimics the human disease was used to determine if an adenoviral vector expressing a human FVlll cDNA could be used to correct the hemophilia A phenotype. Within 48 hours after peripheral vein administration of the vector to FVIII-deficient dogs, the hemophilic phenotype was corrected, based on determination of the activated clotting time, the activated partial thromboplastin time, and the cuti-EMOPHILIA A IS AN X-linked bleeding disorder H caused by a deficiency of blood coagulation factor VI11 (FVIII). Hemophilia A affects I in 5,000 to 10,000 men and, in the severe form, is a life-threatening, crippling disease.' Infusion of plasma-derived or recombinant FVIII in response to bleeding crises is currently the most widely accepted therapy.' Whereas prophylactic treatment of hemophilia A reduces the frequency and severity of bleeding episodes, such treatment is limited by the availability and high cost of purified FVIII, the short half-life of FVIII in vivo, and difficulties associated with repeated intravenous administration. ' Gene therapy for hemophilia A, which would furnish constant blood levels of FVIII, would be a significant treatment improvement. Hemophilia A has been widely discussed as a candidate disease for gene therapy for several reasons. L' (1) the molecular biology and biochemistry of FVIII and hemophilia A are well understood; (2) increasing plasma FVIII activity to 5% to 10% of normal would provide a significant clinical improvement; ( 3 ) current treatment is not curative; and (4) a canine model that closely mimics the human disease is available to evaluate new therapeutic products.
Hemophilia A is a severe bleeding disorder caused by a deficiency in clotting factor Vlll (FVIII). A canine model that closely mimics the human disease was used to determine if an adenoviral vector expressing a human FVlll cDNA could be used to correct the hemophilia A phenotype. Within 48 hours after peripheral vein administration of the vector to FVIII-deficient dogs, the hemophilic phenotype was corrected, based on determination of the activated clotting time, the activated partial thromboplastin time, and the cuti-EMOPHILIA A IS AN X-linked bleeding disorder H caused by a deficiency of blood coagulation factor VI11 (FVIII). Hemophilia A affects I in 5,000 to 10,000 men and, in the severe form, is a life-threatening, crippling disease.' Infusion of plasma-derived or recombinant FVIII in response to bleeding crises is currently the most widely accepted therapy.' Whereas prophylactic treatment of hemophilia A reduces the frequency and severity of bleeding episodes, such treatment is limited by the availability and high cost of purified FVIII, the short half-life of FVIII in vivo, and difficulties associated with repeated intravenous administration. ' Gene therapy for hemophilia A, which would furnish constant blood levels of FVIII, would be a significant treatment improvement. Hemophilia A has been widely discussed as a candidate disease for gene therapy for several reasons. L' (1) the molecular biology and biochemistry of FVIII and hemophilia A are well understood; (2) increasing plasma FVIII activity to 5% to 10% of normal would provide a significant clinical improvement; ( 3 ) current treatment is not curative; and (4) a canine model that closely mimics the human disease is available to evaluate new therapeutic products.
Although considerable progress has been made in the development of gene therapy strategies for hemophilia B (factor IX deficiency), FVIII gene therapy has been problematic.3" FVIII must be secreted directly into the plasma".7 and must be complexed with von Willebrand factor (vWF) for protection from proteolytic degradation.* Furthermore, expression of FVIII is inhibited by transcriptional silencers
The publication co.st.7 of this urticle were defrayed in part by page charge puynimr. This urticltr must therefbrr be hereby murked "advertisement" in accordance with I8 U.S.C. section I734 solely to indicate this fact. cently, short-term expression of therapeutic levels of human FVIII in mice has been achieved via ex vivo gene transfer strategies."' However. the necessity for ex vivo cell manipulation and reimplantation is a limitation to the application of gene therapy in large animal models and humans.
As an alternative approach to gene therapy of hemophilia A, we have developed adenoviral vectors for the in vivo delivery of a human FVllI cDNA."'." Adenoviral vectors are attractive for in vivo FVIII gene delivery because a peripheral vein injection in rodents"," results in efficient transduction of hepatocytes that are cells capable of secreting FVIII directly into the circulation.x Furthermore, high-level expression of human FVIII can be achieved in normal, adult mice treated with an adenoviral vector.'0-'' Human FVIII expression in the mice was sustained at levels fourfold greater than the human therapeutic range for at least 22 weeks." However, the efficacy of adenoviral-mediated delivery and expression of human FVIII in a clinically relevant large animal model had not been evaluated.
Canine hemophilia A, first reported approximately 50 years ago, has been thoroughly characterized as a model of hemophilia A in humans."." Plasma-derived and recombinant human FVIII protein corrects the bleeding disorder in FVIII-deficient dogs.'4.27~1'1 Furthermore. treated dogs frequently develop FVIII inhibitors,"." which is a common problem in human hemophilia A patients." In this work, we have extended our investigations to a canine model of hemophilia A and show efficient adenoviral-mediated gene transfer and high-level human FVlll expression in the treated dogs. Hepatic expression of human FVIII resulted in phenotypic correction of the coagulation deficiency in the hemophilia A dogs.
MATERIALS AND METHODS
Experimental animals und adenoviral vector. The experimental animals used in this study were mixed-breed dogs from the hemophilia A colony housed at Auburn University." The adenoviral vector, AvIALAPH81, contains if mouse albumin promoter, the first exon, first intron, and second exon to the translation initiation codon (ATG) of the human apolipoprotein AI gene fused to the B-domaindeleted (BDD) FVIII cDNA in a viral backbone devoid of most El and E3 sequences." The vector was purified and titered by plaque For personal use only. on October 27, 2017. by guest www.bloodjournal.org From assay on 293 cells, as described." A polymerase chain reaction (PCR) assay directed at Ela sequences35 verified that the vector preparation contained less than 10 plaque forming units (pfu) of replication competent adenovirus per 10' pfu. The adenoviral vector was diluted in 10 to 20 mL of Plasma-Lyte (Baxter Health Care Corp, Deerfield, IL) containing 1 % heat-inactivated autologous serum and was administered through an in-dwelling cephalic vein catheter by slow infusion over 5 to 10 minutes. The number of hepatocytes per dog is estimated to be 2.0 X 10" cells per 10 kg of body weight.36 Dog B received cyclophosphamide (1 mgkg; Mead, Johnson, Bristol Myers, Squib, Princeton, NJ) and prednisone (2 mgkg; Roxane Laboratories, Inc, Columbus, OH) daily orally beginning 2 days before vector treatment and continuing for 24 days thereafter. Dog C received cyclosporin A (CsA; 10 mglkg; Sandoz Laboratories, East Hanover, NJ) orally twice a day beginning 3 days before vector administration until day 60 after treatment. All animals were housed es accredited by the American Association for the Accreditation of Laboratory Animal Care and experimental protocols were approved by the Institutional Animal Care and Concern Committee.
The activated clotting time (ACT) and the activated partial thromboplastin time (APTT) assays were performed in the Clinical Pathology Laboratory at the Aubum University School of Veterinary Medicine. The reference values for normal dogs in this laboratory are less than 2 minutes for the ACT and 10 to 14 seconds for the The activated clotting time (ACT)" was measured as follows: 2 mL of blood was collected into a prewarmed (37°C) ACT tube containing 6 to 10 mg of siliceous earth (Becton Dickinson VACUTAINER Systems, Rutherford, NJ); the sample was mixed by inverting the tube five times. After 1 minute of incubation at 3 7 T , the tube was removed from the heating block at 15-second intervals to observe the appearance of the first visible clot. To measure the AF'TT?* plasma samples were obtained from blood collected with 0.109 moVL trisodium citrate at a 9:l ratio. One hundred microliters of actin cephaloplastin (Baxter) was added to 100 pL of plasma and prewarmed to 37°C for 3 minutes. One hundred microliters of prewarmed 0.02 molL calcium chloride (Baxter) was added and the time to initial clot formation was determined with a fibrometer (Becton Dickinson and Co, Cockeysville, MD). The cuticle bleeding time (CBT), an in vivo test sensitive to discrete coagulation factor deficiencies,26 was performed as follows. Dogs were lightly anaesthetized and placed in a supine position, and the fur around a nail was clipped. The nail was then severed directly proximal to the dorsal nail groove and the time in minutes until clot formation was recorded.
The FVIII biologic activity was quantitated using the Coatest chromogenic bio-assay (Chromogenic, Molndal, Sweden). Coatest measures the FVIII-dependent generation of factor Xa from factor X, with 1 U defined as the amount of FVIII activity in 1 mL of pooled human plasma (100 to 200 ng/mL).39.40 Pooled human plasma (George King Bio-Medical, Inc, Overland Park, KS) was used as the FVIII activity standard. Human FVIII antigen levels were quantitated by enzyme-linked immunosorbent assay (ELISA)." Full-length recombinant FVIII protein, supplied by Genetics Institute (Cambridge, MA) was used to generate a standard curve ranging from 1 to 100 ng/mL. BDD FVIII protein (Genetics Institute) and full-length recombinant FVIII were similarly quantitated by this ELISA. Normal dog plasma samples did not interfere with the assay and the limit of sensitivity with dog plasma samples containing BDD FVIII was 3 ng/mL. Samples were diluted 1:5 to 1:lO for the ELISA. No human FVIII antigen was detected in plasma from untreated normal dogs.
The Bethesda assay was used to measure FVIII inhibitors by the one-stage m e t h~d .~' Various dilutions of test plasmas were mixed 1: 1 with a normal human plasma pool and incubated at 37°C for 2 hours and the clot time was determined with the one-stage A m assay. The dilution with residual activity closest to 50% was used
Coagulation and FVIII-spec$c assays.
to calculate the inhibitor titer, in which 50% residual FVIII activity equals 1 Bethesda unit (BU)/mL. DNA and RNA were isolated from liver and spleen biopsy samples as described." Twenty micrograms of each DNA sample was digested with BamHI and subjected to Southem analysis. The probe, prepared by random oligonucleotide priming, contained human FVIII cDNA sequences from +73 to +1345?2.43 Copy number control standards were prepared by adding 1.2 ng, 120 pg, or 12 pg of AvIALAPH81 viral DNA, equivalent to 10, 1, and 0.1 vector copies per cell, respectively, to 20 pg of normal dog liver genomic DNA and digesting with BamHI. The band intensities were quantitated with a Molecular Dynamics PhosphoImager SF (Sunnydale, CA). RNAse protection analysis was performed using the RNAse Protection Kit I1 (Ambion, Austin, TX). For each sample, 50 p g of total cellular RNA was hybridized with 50,000 cpm of a gel-purified RNA probe (see below), digested with the RNAse A/T1 solution provided with the kit diluted 1:100, processed as directed, and analyzed on an 8% polyacrylamide-8 moVL urea gel (SequaGel; National Diagnostics, Atlanta, GA). 32P-labeled fragments from Hpa 11-digested pBR322 were used as DNA size markers. The FVIII probe template, pGemSRpr, has been described." The glyceraldehyde 3-phosphate dehydrogenase (GAP) probe template was generated from the pTRI-GAPDH mouse plasmid (Ambion) digested with Sty I. Antisense RNA probes were synthesized with SP6 polymerase and a-32P-CTP (3,000 Cdmmol; Amersham, Arlington Heights, IL). To verify that the probe concentration in the reactions was in excess of the targeted RNA, an RNAse protection assay was performed in which 50,000 cpm of the human FVIII-specific probe was hybridized to increasing concentrations (25, 50, 75 , and 100 p g ) of mouse liver RNA isolated from a mouse that had received a high dose (4 X lo9 pfu) of AvlA-LAPH81" (data not shown). The signal increased in proportion to the amount of RNA added, showing that the probe was in excess, and analysis of the band intensities with a Molecular Dynamics PhosphoImager SF demonstrated that the assay was quantitative.
Southern analysis and RNAse protection assay.

RESULTS
Correction of the hemophilia A phenotype. The recombinant adenoviral vector, AvlALAPH81, contains a human BDD FVIII cDNA expressed from a modified version of the mouse albumin promoter and incorporates the first intron of the human apolipoprotein A1 gene in the upstream untranslated region.2' Removal of the B-domain from the FVIII protein has no effect on function, activity, or immunogenicity of the p r~t e i n . '~,~,~~ Av1ALAPH8 1 was administered to a 32-kg hemophilic dog, dog A, by cephalic vein infusion ( Table 1 ). The ACT3' and APTT"* were determined before and at days 2, 4, and 7 after AvlALAPH81 administration (Fig 1A and B) . The ACT and APTT were both abnormal before treatment. Within 2 days after vector administration these clotting parameters normalized but retumed to pretreatment values by day 7. The CBT,26 which was greater than 20 minutes before Av 1ALAPH8 1 administration, decreased to 2 minutes by day 2. On day 7, the CBT was 7.5 minutes, which is still within the normal range of 2 to 8 minutes.26 Normalization of the coagulation parameters showed the complete correction of the canine hemophilic phenotype.
FVIII biologic activity was determined by analysis of plasma samples collected before vector administration and daily for 7 days after treatment using Coatest, a FVIII chromogenic bioassay (Fig 1C) . FVIII biologic activity was not detected in plasma samples collected before Av 1ALAPH8 1 treatment. However, at days 1 to 5 after treatment, plasma FVIII activity showed a dramatic increase. FVIII expression peaked ' 2 days after treatment at greater than 8,000 mUlmL. These levels are eightfold higher than the FVIII levels found in normal human p l a~m a . '~.~ By day 7, FVIII plasma levels had decreased below the level of detection.
Plasma samples were also assayed by an ELISA specific for human FVII12' to verify that the FVIII activity measured in the hemophilic dog plasma was vector-derived ( Fig ID) . Human FVIII antigen was not detectable in the plasma before vector administration. At days 1 through 5, high levels of human FVIII were detected. The Coatest activity units and human FVIII antigen levels measured by ELISA were in good agreement, indicating that the FVIII was fully functional. Human FVIII was also detected in the dog plasma Days P o s t -T r e a t m e n t with an ELISA in which the detection antibody was directed against canine vWF (data not shown). Consistent with the results of previous these data show that the human FVIII protein complexed normally with canine vWF in the FVIII-deficient dog. Normalization of the clotting parameters and high-level human FVIII expression in the affected dog showed that the hemophilic phenotype can be completely corrected by adenoviral vector-mediated delivery of the BDD FVIII cDNA.
To assess vector DNA levels and FVIII gene expression, hepatic and splenic biopsies were performed 7 days after vector administration. DNA and RNA isolated from liver and spleen were assayed by Southern and RNAse protection analyses (Fig 2) . Vector Vector persistence in transduced dogs. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From DNA was present in both liver and spleen at an average of approximately 5 to I O copies per cell, but was not detectable in liver before vector administration (Fig 2A) . The RNA analysis showed the presence of vector-derived FVIII RNA only in the liver biopsy sample (Fig 2B) . Comparison to the human FVIII-specific RNA detected in a mouse that was expressing human FVIll at levels greater than 1,000 nglml" (lO.000 to 20,000 mU/mL; Fig 2C) showed that the dog and mouse liver RNA samples contained similar amounts of human FVIII RNA. Human FVIII-specific RNA was not detected in the canine spleen biopsy sample, although the spleen contained more vector copies per cell than the liver. Thus, the albumin promoter remained transcriptionally active 7 days after vector administration and, consistent with previous observations in mice," the albumin promoter functioned in a liver-specific manner in the dog. As expected, human FVIII-specific RNA was not detected in the preinjection liver sample or in the normal dog liver RNA sample. Taken together, these results indicate that the decline in human FVIII expression was not due to a complete loss of vector DNA from the treated animal or to the transcriptional inactivation of the albumin promoter.
Expression is limited by antibodies to human FVIII. FVIII-deficient dogs have previously been shown to rapidly develop inhibitory antibodies to human FVllI within I to 2 weeks after exposure to the human protein.'' This observation provides a likely explanation for the decrease in FVIlI plasma levels between 5 to 7 days after treatment (Fig 1 ) . The Bethesda assay, a standardized test to quantitate inhibitors in hemophilic patients:' was used to measure FVllI inhibitors in pretreatment and day-7 posttreatment plasma samples. A value of 1 BU was measured in the pretreatment plasma sample (Table I) . At day 7, the antibody titer had increased to I85 BU, showing the development of FVIlI inhibitors in the treated dog. Therefore, the limited duration of expression of human FVIII in the hemophilic dog was due, at least in part, to the development of antibodies to the human protein. Dog A did not survive a surgical biopsy and died from bleeding complications.
To minimize the humoral immune response to human FVIII, a second 19-kg FVIII-deficient dog, dog B, was immunosuppressed with cyclophosphamide and prednisone before and after vector administration (Table l) . At 2 to 10 days after treatment, the ACT and AFTT approached the normal range, thus showing phenotypic correction in the second dog (Fig 3A and B) . Evaluation of FVIll activity by Coatest showed FVlll expression at amounts well above human therapeutic levels that were sustained for I O days (Fig 3C) . However, plasma levels were lower than those achieved in dog A. The Bethesda assay:' performed using plasma samples collected from dog B, measured 0 BU before vector administration (Table I) . However, by days 7 and 14, the antibody titer had increased to 14 BU and 30 BU, respectively. Therefore, the immunosuppressive treatment did not prevent the development of an antibody response to human FVIll and. consequently, did not substantially prolong FVIll expression in this animal. A biopsy was not performed on dog B.
Based on previous studies with adenoviral vectors, the persistence of FVlll expression in the treated dogs may also Therefore, a third, 22-kg, FVIII-deficient dog, dog C, was immunosuppressed with CsA before and after AvlA-LAPH81 vector administration ( Table 1) . No significant improvement of clotting parameters were observed in this dog, and FVIII activity was undetectable (data not shown). To assay for the presence of human FVIII antibodies, a Bethesda assay4' was performed using pretreatment and day-7 plasma samples. No Bethesda titer was detected at either time point, indicating the lack of inhibitors to human FVIII (Table I) .
To measure vector transduction in dog C, liver and spleen biopsies were performed 14 days after vector treatment. Southern analysis of DNA isolated from the biopsy samples showed a significant, although lower level of liver and spleen transduction in dog C compared with the day-7 biopsy samples obtained from dog A (Fig 4A) . A second biopsy at 60 days showed that vector DNA remained in the liver, although at fivefold lower levels than detected at 14 days (data not shown). However, FVIII RNA could not be detected by RNAse protection analysis (Fig 4B) , indicating that the vector was not expressing the FVIII cDNA in this animal.
DISCUSSION
We have shown complete correction of canine hemophilia A by in vivo gene therapy. A noninvasive, peripheral vein injection of an FVIII adenoviral vector to hemophilia Aaffected dogs resulted in normalization of clinical clotting parameters and expression of human FVIII in the plasma at amounts well above human therapeutic levels. Previous studies performed in normal adult mice showed that the FVIII adenoviral vector could achieve high plasma levels of human FVIII.21,22 However, the effectiveness and feasibility of this approach in a clinically relevant large animal model had not been established. substantially improve the duration of phenotypic correction. A similar immunosuppressive regimen also showed limited success when used t o treat human patients with high FVIll inhibitor titers." In contrast to human FVIII. the canine FVlll protein is less immunogenic in hemophilic clogs and some dogs can be repeatedly treated with canine plasma without developing inhibitory antibodies.'' The establishnient of sustained phenotypic correction in hemophilic dogs may require the development of ndenoviral vectors that encode the canine cDNA. This strategy would be comparable to treating human hemophiliacs with vectors encoding the human cDNA. Indeed. retroviral and adenoviral vectors encoding the canine factor IX cDNA have been used to treat hemophilia B dogs and expression persisted at low levels (0.1 % of human physiologic levels) for several months.J"-5' No evidence of a humoral immune response to the canine factor IX protein in the treated animals was reported."" 'I Whereas the inhibitory antibody response to human FVlll was sufficient to explain the loss of FVIll expression in dogs A and R. even in the absence of a humoral immune response to the human protein.
sustained FVlll expression also could be limited by :I cellular immune response directed against hepatocytes expressing adenoviral backbone gene products.'"' 'I" It remains unclear why vector treatment of dog C did not result in human FVIll expression. Inhibitory antibodies to human FVlll were not detected before or after vector adniinistration. confirming that human FVIll protein was not expressed in this animal (Table I ) . DNA and RNA analyses of liver and spleen biopsy samples showed that. although dog C was transduced with the vector. no human FVIIIspecific RNA was detected in the liver (Fig 4) . indicating that the vector was not functional. Comparison of the transduction efficiencies of dog A and dog C showed that. although both dogs received a similar dose of vector (Table  I) , dog C had significantly less vector DNA in the liver and spleen than did dog A. Therefore. it is possible that a threshold of vector transduction may exist below which the DNA is not transcribed. Alternatively. lack of vector function in dog C may have been caused by the administration of CsA. Preliminary studies in mice have suggested that CsA may inhibit expression from the FVlll vector by reducing the FVlll RNA levels (data not shown). However. the manner in which CsA may suppress transcription from the vector remains unclear but may be related to interactions with cellular transcription factors.5' The variation in vector function described in this work underscores the importance of evaluating gene therapy in large animal models. such as hemophilic dogs.
One notable finding in this study is that peripheral vein administration of an adenoviral vector to dogs resulted in efficient liver transduction. This observation is consistent with a previous study in which dogs received an adenoviral vector encoding the P-galactosidase or human FIX cDNA (Mnuser et al. manuscript submitted). Preferential accumulation of adenoviral vectors in liver has been described in and the extension of this phenomenon to large animals lends credence to the intravenous use of these vectors in humans. Interestingly, the tissue distribution of vector in the dog model differed from that observed in mice: after intravenous vector administration, mouse spleens were transduced ;it only I % to 3% ofthe level seen in liver,"." whereas the dog spleen was transduced with more vector copies per cell than the liver (Figs 2 and 4) . The explanation for this disparity is not clear and may represent differences in the vector tropism in the two models or simply more efficient lnice,?l.?J
